A rhinitis treatment patch, system and method for providing stimulation to a human

Abstract

The present application relates to rhinitis treatment technical field, especially a kind of rhinitis treatment paste, system and method for providing stimulation to human body, wherein rhinitis treatment paste, including patch body;Electrode group, including respectively set on patch body positive electrode and negative electrode, and the positive electrode and negative electrode form stimulation loop.Using patch design, small and portable;Medical grade material and independent loop design, avoid current diffusion, guarantee use safety.Through the combination of non-cross nasal loop and cross nasal loop, it can be adapted to unilateral inflammation, bilateral inflammation and light and heavy difference scene, avoid invalid stimulation to healthy tissue.

Description

Technical Field

[0001] This invention relates to the field of rhinitis treatment technology, and in particular to a rhinitis treatment patch, a system and method for providing stimulation to the human body. Background Technology

[0002] Existing rhinitis treatment devices have many significant shortcomings in practical applications, with structural design issues being particularly prominent. The integration of their core treatment units and auxiliary components is low, resulting in a complex and redundant overall structure. This design flaw directly leads to the devices being too large; most products are nearly the size of small household appliances, making them extremely impractical for portability.

[0003] From a usage scenario perspective, such devices are difficult to meet users' needs for treatment at home anytime, as their size necessitates fixed placement and prevents flexible movement. Furthermore, they are unsuitable for commuting or business trips, taking up significant space and being inconvenient to operate. This severe limitation on usage scenarios greatly weakens the continuity and convenience of treatment, ultimately affecting the overall treatment effectiveness. Summary of the Invention

[0004] In this section, as well as in the abstract and title of this application, some simplifications or omissions may be made to avoid obscuring the purpose of this section, the abstract, and the title of this application, and such simplifications or omissions shall not be used to limit the scope of the invention.

[0005] To address the shortcomings of existing technologies, one objective of this invention is to provide a rhinitis treatment patch, comprising a patch body and an electrode assembly, which includes a positive electrode and a negative electrode respectively disposed on the patch body, wherein the positive electrode and the negative electrode form a stimulation circuit.

[0006] As a preferred embodiment of the rhinitis treatment patch of the present invention, the patch body includes a nasal support portion adapted to the bridge of the nose, and connecting portions disposed on both sides of the nasal support portion; the positive electrode and negative electrode of the electrode group are both disposed on the connecting portions; the stimulation circuit includes a non-transnasal circuit formed between the positive electrode and the negative electrode of the same side connecting portion, and / or includes a transnasal circuit formed between the positive electrode and the negative electrode of the opposite side connecting portion.

[0007] As a preferred embodiment of the rhinitis treatment patch of the present invention, wherein: both the non-cross-nasal circuit and the cross-nasal circuit are provided in twos; the positive electrode and the negative electrode of one non-cross-nasal circuit are respectively the positive electrode of one cross-nasal circuit and the negative electrode of the other cross-nasal circuit; and a first switch is provided on a single non-cross-nasal circuit and a second switch is provided on a single cross-nasal circuit.

[0008] In a preferred embodiment of the rhinitis treatment patch of the present invention, two non-cross-nasal circuits are provided, and the two non-cross-nasal circuits are respectively located on the left and right sides of the vertical axis of symmetry of the rhinitis treatment patch; wherein the positive and negative ends of the non-cross-nasal circuit on the left side can communicate with the human tissues of the two perinasal acupoints 300 located on the left side of the vertical axis of symmetry of the rhinitis treatment patch, and the positive and negative ends of the non-cross-nasal circuit on the right side can communicate with the human tissues of the two perinasal acupoints 300 located on the right side of the vertical axis of symmetry of the rhinitis treatment patch.

[0009] As a preferred embodiment of the rhinitis treatment patch of the present invention, wherein: a cross-nasal circuit is provided; the positive and negative ends of the cross-nasal circuit can communicate with human tissues located at two perinasal acupoints 300 on the left and right sides of the vertical axis of symmetry of the rhinitis treatment patch.

[0010] As a preferred embodiment of the rhinitis treatment patch of the present invention, the nasal transcutaneous circuit is provided in two parts; the positive and negative ends of each nasal transcutaneous circuit can be connected to the human tissue at two perinasal acupoints 300 located on the left and right sides of the vertical axis of symmetry of the rhinitis treatment patch.

[0011] In a preferred embodiment of the rhinitis treatment patch of the present invention, the positive electrode includes a base layer, a flexible layer, and a conductive layer disposed between the base layer and the flexible layer, wherein the conductive layer is provided with an array of conductive needles.

[0012] As a preferred embodiment of the rhinitis treatment patch of the present invention, the patch body has a stretching section in the middle section, the stretching section connects the two ends of the patch body in the lateral direction, and the lateral deformation range of the stretching section is 0-2.5cm.

[0013] Another objective of this invention is to provide a system for providing stimulation to the human body, comprising: a data acquisition module for acquiring pressure data from both nasal cavities, determining whether there is inflammation based on the pressure data, and generating inflammation severity data based on the pressure data; an electrical stimulation module for applying electrical stimulation to acupoints 300 around the nose corresponding to the inflamed nasal cavity; and a control module for switching the operation of the corresponding electrical stimulation module based on the received results of whether there is inflammation in both nasal cavities, and adjusting the current intensity and frequency of the electrical stimulation module based on the inflammation severity data of both nasal cavities if inflammation exists in both nasal cavities.

[0014] Another objective of this invention is to provide a method for providing stimulation to the human body, comprising: collecting pressure data from both nasal cavities to determine whether there is inflammation; if inflammation is present, generating inflammation severity data based on the pressure data; if inflammation is present in only one nasal cavity, switching to a single electrical stimulation module to perform electrical stimulation on the corresponding perinasal acupoint 300; if inflammation is present in both nasal cavities, switching to multiple electrical stimulation modules to perform electrical stimulation on the corresponding perinasal acupoint 300; the current intensity and frequency of the electrical stimulation modules are adjusted according to the nasal inflammation severity data.

[0015] The beneficial effects of this invention are: It adopts a patch design, making it small and portable; medical-grade materials and an independent circuit design prevent current diffusion and ensure safe use. By combining non-transnasal and transnasal circuits, it can adapt to unilateral inflammation, bilateral inflammation, and scenarios with varying degrees of severity, avoiding ineffective stimulation of healthy tissues. Attached Figure Description

[0016] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the following description of the embodiments will be briefly introduced. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0017] Figure 1 This is the first structural diagram of the nasal inflammation treatment patch of the present invention.

[0018] Figure 2 This is the first structural diagram of the nasal inflammation treatment patch of the present invention.

[0019] Figure 3 This is a usage scenario illustration of the nasal inflammation treatment patch of the present invention.

[0020] Figure 4 This is a structural diagram of the positive electrode of the present invention.

[0021] Figure 5 This is a schematic diagram of the rhinitis treatment patch in Example 3.

[0022] Figure 6 This is a schematic diagram of the rhinitis treatment patch in Example 4.

[0023] Figure 7 This is a schematic diagram of the rhinitis treatment patch in Example 5.

[0024] Figure 8 This is a schematic diagram of the rhinitis treatment patch in Example 6.

[0025] Figure 9 This is a schematic diagram of the rhinitis treatment patch in Example 7.

[0026] Figure 10This is a wiring diagram of the system for providing stimulation to the human body in Example 8. Detailed Implementation

[0027] To make the objectives, features, and advantages of the present invention more apparent and understandable, the specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings.

[0028] Many specific details are set forth in the following description in order to provide a full understanding of the invention. However, the invention may also be practiced in other ways different from those described herein, and those skilled in the art can make similar extensions without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below.

[0029] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The phrase "in one embodiment" appearing in different places in this specification does not necessarily refer to the same embodiment, nor is it a single or selective embodiment that is mutually exclusive with other embodiments.

[0030] Example 1

[0031] Reference Figure 1 and Figure 3 This embodiment is the first embodiment of the invention, including a patch body 100 and an electrode assembly 200.

[0032] First, it's worth noting that the core acupoints related to rhinitis stimulation around the nose include: the left Shangyingxiang acupoint (at the junction of the alar cartilage and the left nasal concha), and the left Yingxiang acupoint (beside the midpoint of the outer edge of the left nasal ala, in the nasolabial groove); the right Shangyingxiang acupoint (at the junction of the alar cartilage and the right nasal concha), and the right Yingxiang acupoint (beside the midpoint of the outer edge of the right nasal ala, in the nasolabial groove). These four acupoints are all part of the 300 acupoints around the nose (different locations with complementary functions) and are key targets for electrostimulation therapy.

[0033] Furthermore, it should be noted that the principle of electrostimulation therapy for rhinitis is as follows: By applying electrical stimulation to the aforementioned acupoints, a triple therapeutic effect can be achieved. First, it regulates the nervous system, inhibiting excessive excitation of the trigeminal nerve endings in the nasal mucosa, reducing reflex symptoms such as sneezing and nasal itching; it balances the autonomic nervous system, inhibiting parasympathetic hyperactivity, and reducing glandular secretion and vasodilation. Second, it improves local circulation, promoting vasodilation around the nose, increasing blood flow to the nasal mucosa, accelerating the clearance of inflammatory factors such as histamine, and enhancing the ciliary movement function of the nasal mucosa. Third, it suppresses inflammation, activating the endogenous anti-inflammatory system, such as releasing endorphins, reducing mast cell activity, and alleviating nasal mucosal edema.

[0034] Electrode assembly 200, each containing a positive electrode 201 and a negative electrode 202, is made of medical-grade metal. In use, electrode assembly 200 is placed on the face, with each position corresponding to one of the two acupoints 300 around the nose. For example, the left electrode assembly 200 corresponds to the upper left Yingxiang and lower left Yingxiang acupoints, and the same applies to the right side.

[0035] Example 2

[0036] Reference Figures 1-4 This is the second embodiment of the invention, and this embodiment is based on embodiment 1.

[0037] Specifically, the patch body 100 includes a nose pad portion 103 adapted to the bridge of the nose, and connecting portions 102 provided on both sides of the nose pad portion 103. The positive electrode 201 and negative electrode 202 of the electrode assembly 200 are both provided on the connecting portions 102.

[0038] A non-cross-nasal circuit 401 refers to a stimulation circuit 400 in which the positive electrode 201 and the negative electrode 202 of an electrode group 200 are located on the same side of the nose and do not cross the bridge of the nose. For example, in a left-side non-cross-nasal circuit 401, the positive electrode 201 contacts the left Shangyingxiang acupoint, and the negative electrode 202 contacts the left Yingxiang acupoint. The current passes through the left perinasal tissue to form a closed non-cross-nasal circuit 401.

[0039] A transnasal circuit 402 refers to a stimulation circuit 400 in which the positive electrodes 201 of an electrode group 200 are located on the left and right sides of the nose, respectively. For example, the positive electrode 201 contacts the left Shangyingxiang acupoint, and the negative electrode 202 can contact the right Shangyingxiang acupoint or Yingxiang acupoint. The current passes through the facial tissue below the bridge of the nose to form a transnasal circuit 402.

[0040] Non-cross-nose loops 401 and cross-nose loops 402 can exist simultaneously or individually, such as left non-cross-nose loop 401 + right non-cross-nose loop 401 + 1 cross-nose loop 402; the number of m non-cross-nose loops 401 and the number of n cross-nose loops 402 are both positive integers ≥ 1.

[0041] This embodiment allows for the separate configuration of individual nasal treatment patches with varying numbers of electrode groups, depending on the quantities of m and n, or these patches can be integrated into a single patch. Compared to existing nasal treatment devices, the nasal treatment patch, shaped like a nasal strip, achieves miniaturization. Furthermore, this embodiment, through the flexible combination of m and n, can cover various nasal inflammation scenarios, including unilateral inflammation, bilateral inflammation, and unilateral severe / bilateral mild cases, overcoming the limitation of existing devices that can only stimulate both sides simultaneously. The positive electrode 201 and negative electrode 202 correspond to acupoints around the nose 300, avoiding the limitations of stimulating a single acupoint and enhancing the therapeutic effect through the synergistic effect of multiple acupoints. The independent controllability of the circuit also prevents excessive current diffusion to non-treatment areas (such as the eyes and mouth), reducing the risk of accidental injury.

[0042] Preferably, the positive electrode 201 employs a composite layer design to ensure conductivity and adhesion. It includes a base layer 201a, made of polyimide with a thickness of 0.1 mm, possessing high temperature resistance and good flexibility, serving as the structural support for the positive electrode 201 and fixedly connected to the patch body 100. A conductive layer 201c is located above the base layer 201a, made of gold-plated copper foil with a thickness of 5 μm, and its surface is etched with a grid-like conductive path, with a resistance ≤50Ω. A conductive needle array 201c-1 is distributed on it—the needles are made of titanium alloy, 0.2-0.3 mm in length, penetrating only the stratum corneum of the skin to avoid pain, with a spacing of 0.5 mm, used to enhance conductive contact with the skin and solve the problem of poor contact caused by skin oil and sweat. A flexible layer 201b covers the surface of the conductive layer 201c, made of medical-grade gel, and comes into direct contact with the skin, reducing skin irritation.

[0043] Furthermore, specifically, the shape of the patch body 100 in this embodiment is similar to a nasal strip. The patch body 100 can be made of medical-grade flexible silicone material with a thickness of 0.3-0.5mm, which can closely fit the bridge of the nose, the alar of the nose, and the nasolabial fold area. The stretching section 101 is located in the middle section of the patch body 100, corresponding to the area directly above the bridge of the nose. Its initial length is 1cm, and it connects the two ends of the patch body laterally, with the left side corresponding to the left nasal periphery and the right side corresponding to the right nasal periphery.

[0044] Made of medical-grade elastic polyurethane, with a lateral stretching range of 0-2.5cm, it can adapt to different users' nasal bridge widths, including adult and child nasal bridge widths. By stretching and adjusting the lateral length of the patch body 100, it ensures that the electrode groups 200 on the left and right sides can be accurately aligned with the acupoints of different users, avoiding electrode group 200 misalignment caused by differences in facial bone structure.

[0045] The three-layer structure balances conductivity, flexibility, and durability, enhancing adaptability. The stretchable section 101 is dynamically adjustable, solving the wearing adaptation problem for users of different ages and face shapes, and meeting the fitting requirements of acupoints.

[0046] Example 3

[0047] Reference Figure 5 This is the third embodiment of the invention, and this embodiment is based on embodiment 2.

[0048] In this embodiment, the rhinitis treatment patch has only one non-cross-nasal circuit 401. When rhinitis only affects one nasal cavity, such as when the left nasal cavity is congested, the rhinitis treatment patch has only one non-cross-nasal circuit 401, m=1. Specifically, the non-cross-nasal circuit 401 is located on the left or right side of the nose, depending on the side of inflammation. The positive electrode 201 is attached to the left Shangyingxiang acupoint, and the negative electrode 202 is attached to the left Yingxiang acupoint. These two are the "perinasal acupoints 300" on the left side. The current flows out from the positive electrode 201, through the left Shangyingxiang acupoint → left perinasal subcutaneous tissue → left Yingxiang acupoint → negative electrode 202, forming a closed circuit, which only provides targeted stimulation to the inflamed area on the left side.

[0049] This embodiment enables precise unilateral treatment. The m=1 design avoids ineffective stimulation of the healthy nasal cavity, saves energy, and reduces the risk of damage to normal tissue.

[0050] Example 4

[0051] Reference Figure 6 This is the fourth embodiment of the invention, and this embodiment is based on embodiment 2.

[0052] When there is inflammation in both nasal cavities, but the degree of inflammation differs between the two sides (e.g., the left side is more severe than the right side), two non-transnasal circuits can be set up, m=2.

[0053] The positive electrode 201 of the left non-cross-nasal circuit 401 is attached to the left upper Yingxiang acupoint, and the negative electrode 202 is attached to the left Yingxiang acupoint. Similarly, the positive electrode 201 of the right non-cross-nasal circuit 401 is attached to the right upper Yingxiang acupoint, and the negative electrode 202 is attached to the right Yingxiang acupoint. The two non-cross-nasal circuits 401 are completely independent, and the current paths do not intersect. For example, the current intensity on the left can be set to 1.5mA at a high frequency of 50Hz, and on the right to 1mA at a low frequency of 30Hz, adapting to the differences in inflammation between the two sides. In the left non-cross-nasal circuit 401, the current flows from the upper left Yingxiang acupoint to the left perinasal tissue, then to the lower left Yingxiang acupoint, and finally to the left negative electrode 202; in the right non-cross-nasal circuit 401, the current flows from the upper right Yingxiang acupoint to the right perinasal tissue, then to the lower right Yingxiang acupoint, and finally to the right negative electrode 202. The currents on both sides do not interfere with each other, achieving personalized treatment with strong stimulation on the left and weak stimulation on the right. Independent adjustment on both sides overcomes the limitation of existing treatment devices having the same current intensity on both sides, allowing for precise matching of stimulation parameters based on the degree of inflammation on both sides.

[0054] Simultaneous stimulation of 300 acupoints around the nose on both sides can enhance the overall anti-inflammatory effect through the interaction of meridians.

[0055] Example 5

[0056] Reference Figure 7 This is the fifth embodiment of the invention, and this embodiment is based on embodiment 2.

[0057] When bilateral nasal inflammation is closely related, such as when allergic rhinitis causes bilateral nasal congestion, a transnasal circuit 402 can also be set up, n=1.

[0058] The positive electrode 201 is attached to the left upper Yingxiang acupoint, and the negative electrode 202 is attached to the right Yingxiang acupoint, which together constitute "300 acupoints around the nose on both sides". The current path is as follows: left upper Yingxiang → subcutaneous connective tissue below the bridge of the nose → right Yingxiang → negative electrode 202, forming a closed circuit across the bridge of the nose.

[0059] The current in the transnasal circuit 402 can act on both sides of the perinasal tissues simultaneously. The left path is as follows, stimulating the left Shangyingxiang acupoint to improve the microcirculation of the left nasal mucosa; the right path is as follows, stimulating the right Yingxiang acupoint to inhibit excessive secretion of the right gland; the middle path (across the bridge of the nose) is as follows, transmitting signals through the nerve network of the deep facial fascia layer (such as the maxillary branch of the trigeminal nerve) to achieve bilateral synergistic regulation.

[0060] Suitable for scenarios with simultaneous bilateral inflammation, this treatment utilizes holistic stimulation via transnasal current to avoid the limitations of individual circuits operating independently. The current covers the combined tissues below the bridge of the nose, acting on shared physiological structures in both nasal cavities (such as the nasal septum mucosa), thus addressing the difficulty of existing treatment devices in covering the nasal septum area.

[0061] Example 6

[0062] Reference Figure 8 This is the fifth embodiment of the invention, and this embodiment is based on embodiment 2.

[0063] For example, when rhinitis is accompanied by complex symptoms such as bilateral nasal congestion, two transnasal circuits 402 can be set up, n=2.

[0064] The first transnasal circuit 402 is as follows: the positive electrode 201 is attached to the left Yingxiang acupoint, and the negative electrode 202 is attached to the right Shangyingxiang acupoint. The second transnasal circuit 402 is as follows: the positive electrode 201 is attached to the left Shangyingxiang acupoint, and the negative electrode 202 is attached to the right Yingxiang acupoint. The two transnasal circuits 402 operate in parallel, with non-overlapping current paths. The first transnasal circuit 402 is positioned slightly lower, and the second transnasal circuit 402 is positioned slightly higher. The first circuit is as follows: left Yingxiang → right Shangyingxiang, focusing on stimulating the nerve endings in the nasolabial groove area, relieving right nasal congestion (Shangyingxiang acupoint is responsible for clearing the nasal passages) and left nasal itching (Yingxiang acupoint is responsible for relieving itching). The second circuit is as follows: left Shangyingxiang → right Yingxiang, focusing on the vascular network above the nasal ala, promoting the reduction of swelling of the left mucosa (the area near Shangyingxiang acupoint is rich in blood vessels) and reducing runny nose on the right (Yingxiang acupoint inhibits glands). The two transnasal circuits 402 achieve targeted treatment by differentiating parameters, such as the first circuit at 20Hz and the second circuit at 30Hz.

[0065] By employing differentiated stimulation from two transnasal circuits 402, multiple complex symptoms such as nasal congestion, nasal itching, and runny nose can be simultaneously relieved, overcoming the limited effectiveness of existing single-stimulation modes in therapeutic devices. The currents from the two transnasal circuits 402 form a cross-coverage in the nasal bridge area, enhancing stimulation of deeper tissues (such as the anterior ethmoidal nerve) and improving overall treatment efficiency.

[0066] Example 7

[0067] Reference Figure 9 This is the seventh embodiment of the invention, and this embodiment is based on embodiment 2.

[0068] For example, when rhinitis is in a dynamic change phase, such as the inflammation on the left side lessening and the right side worsening, a combination of two non-transnasal circuits 401 and two transnasal circuits 402 is used, with m=2 and n=2, and an on / off control is added. The positive electrode 201 and negative electrode 202 of one non-transnasal circuit 401 are respectively the positive electrode 201 of one transnasal circuit 402 and the negative electrode 202 of the other transnasal circuit 402. Furthermore, a first switch 401a is provided on each non-transnasal circuit 401, and a second switch 402a is provided on each transnasal circuit 402.

[0069] The non-cross-nose circuit 401 is as follows: the left side (upper left wing incense stick → lower left wing incense stick) and the right side (upper right wing incense stick → lower right wing incense stick) are connected in series with the first switch 401a, such as a miniature relay. The cross-nose circuit 402 is as follows: the first circuit (left wing incense stick → upper right wing incense stick) and the second circuit (upper left wing incense stick → right wing incense stick) are each connected in series with the second switch 402a. The first switch 401a and the second switch 402a are connected to the control module 700 (see embodiment 8), and the circuit working state can be switched manually or automatically. For example, the left non-cross-nose circuit 401 can be closed, and the right non-cross-nose circuit 401 + one cross-nose circuit 402 can be opened.

[0070] Example of working mode:

[0071] Acute phase (bilateral severe inflammation): All on, m=2, n=2, non-transnasal circuit 401 strong stimulation (current 2mA), transnasal circuit 402 coordinated modulation (current 1mA).

[0072] Remission period (left side lessened, right side still severe): Close left non-transnasal circuit 401 (first switch disconnected), open right non-transnasal circuit 402 + second circuit, focus treatment on the right side.

[0073] Consolidation phase (mild bilateral inflammation): Close all non-transnasal circuits 401, and open only one transnasal circuit 402 (as in the first circuit), maintaining therapeutic effect with low-intensity stimulation (0.5mA current).

[0074] By controlling the on / off state, the circuit combinations can be flexibly switched to adapt to the symptom changes at different stages of rhinitis, overcoming the limitations of fixed modes in existing treatment devices. It eliminates the need to continuously activate all circuits; ineffective circuits can be shut down based on inflammation severity data, extending battery life.

[0075] Example 8

[0076] Reference Figure 10 This embodiment is the eighth embodiment of the invention, and it is based on embodiment 7. This embodiment provides a system for providing stimulation to the human body.

[0077] The acquisition module 500 can use a pressure sensor to detect the pressure caused by nasal congestion. The pressure sensor can be installed on a rod and placed in the nasal cavity (this is existing technology and will not be described in detail here). It can collect data on whether there is inflammation in both nasal cavities in real time. If there is inflammation, the sensor data is converted into an inflammation degree score.

[0078] The electrical stimulation module 600 includes a multi-output unit (corresponding to the four circuits in Embodiment 7), and the current intensity (0.1-2mA) and frequency (10-100Hz) of each circuit can be independently adjusted. It is electrically connected to the electrode group 200 and outputs stimulation signals according to the instructions of the control module 700.

[0079] Control module 700: Its core is an MCU (microcontroller unit), which receives inflammation data from the acquisition module 500 and performs logical judgments: If inflammation is only on the left side → control the first switch 401a to open the left non-transnasal circuit 401, and the electrical stimulation module 600 outputs the corresponding parameters. If inflammation is bilateral (left side is more severe than right side) → control the left non-transnasal circuit 401 and two transnasal circuits 402 to open, with the left current intensity of 1.8mA being higher than the right current intensity of 1.2mA.

[0080] Workflow: The data acquisition module 500 initializes and completes basic bilateral inflammation detection within 5 seconds. The control module 700 receives the data and determines the side and severity of inflammation. It automatically matches the optimal circuit combination (e.g., bilateral severe → enable m=2, n=2) and adjusts the electrical stimulation parameters. During treatment, the acquired data is refreshed every 30 seconds, and parameters are fine-tuned in real time.

[0081] No manual adjustment is required; the system automatically matches the stimulation protocol, solving the problem of existing therapeutic devices relying on user experience. Parameters are dynamically adjusted based on real-time inflammation data to avoid overstimulation or understimulation. It is compatible with all circuit designs in Examples 3 to 7, offering high scalability.

[0082] Example 9

[0083] Reference Figures 1-10This embodiment is the ninth embodiment of the invention, and it is based on embodiment 6. This embodiment provides a method for providing stimulation to the human body.

[0084] Step 1: Collect the inflammation status of both nasal cavities. The collection module 500 can obtain the inflammation judgment results of the left and right sides through pressure sensors, that is, whether there is inflammation or not.

[0085] Step 2: Collect inflammation severity data. If inflammation is present, calculate the inflammation score (L score, R score, 0-10 points) again on the side with inflammation using a pressure sensor (nasal congestion resistance). Nasal congestion resistance and the calculated inflammation score are positively correlated.

[0086] Step 3: Stimulation control for unilateral inflammation. If inflammation is only present on the left side (R score = 0), the control module 700 sends a command to disconnect the second switch 402a of the right non-transnasal circuit 401 and all transnasal circuits 402. The left non-transnasal circuit 401 is then opened (m = 1), and the electrical stimulation module 600 outputs the following parameters: intensity = L score × 0.2 mA, frequency = 20 Hz (fixed, suitable for relieving itching and swelling).

[0087] Step 4: Control of bilateral inflammation. If inflammation is present bilaterally (L score > 0 and R score > 0),

[0088] If L_score ≥ R_score, open the left non-cross-nose circuit 401 + right non-cross-nose circuit 401 (m = 2) + 1 cross-nose circuit 402 (n = 1), the left intensity = L_score × 0.2mA, the right intensity = R_score × 0.2mA, and the cross-nose frequency = (L_score + R_score) × 2.5Hz.

[0089] If L score < R score, open the right non-cross-nose circuit 401 + 2 cross-nose circuits 402 (n = 2), the right strength = R score × 0.2mA, and the cross-nose strength is taken as the average value.

[0090] Step 5: Dynamic adjustment. Repeat steps 1-2 every minute. If the inflammation score changes by ≥2 points, readjust the stimulation parameters and circuit combination according to steps 3-4.

[0091] Customized stimulation plans are developed based on the differences in inflammation on one or both sides, enhancing the effectiveness of treatment. Real-time tracking of inflammation changes and adjustments to the strategy address the challenge of treating fluctuating rhinitis symptoms. No professional knowledge is required; the entire process is automated, lowering the barrier to home use.

[0092] Finally, to summarize the beneficial effects of the present invention: Through flexible circuit design, adaptable structure (stretch segment 101, flexible layer 201b) and intelligent system for providing stimulation to the human body, the present invention solves the defects of existing rhinitis treatment devices, such as complex structure, inability to provide unilateral stimulation and fixed parameters, and realizes precise, personalized and intelligent electrical stimulation treatment for rhinitis, which has significant clinical application value.

[0093] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all such modifications or substitutions should be covered within the scope of the claims of the present invention.

Claims

1. A system for providing stimulation to the human body, characterized in that: include, Patch body (100); The electrode assembly (200) includes a positive electrode (201) and a negative electrode (202) respectively disposed on the patch body (100), and a stimulation circuit (400) is formed between the positive electrode (201) and the negative electrode (202). The patch body (100) includes a nose pad (103) adapted to the bridge of the nose, and connecting portions (102) provided on both sides of the nose pad (103). The positive electrode (201) and the negative electrode (202) of the electrode group (200) are both provided on the connecting portions (102). The stimulation circuit (400) includes a non-transnasal circuit (401) formed between the positive electrode (201) and the negative electrode (202) on the same side of the connection (102), and / or a transnasal circuit (402) formed between the positive electrode (201) and the negative electrode (202) on the opposite side of the connection (102). Both the non-cross-nose circuit (401) and the cross-nose circuit (402) are provided in twos. The positive electrode (201) and the negative electrode (202) of one of the non-cross-nose circuits (401) are respectively the positive electrode (201) of one of the cross-nose circuits (402) and the negative electrode (202) of the other cross-nose circuit (402). A first switch (401a) is provided on a single non-cross-nose circuit (401), and a second switch (402a) is provided on a single cross-nose circuit (402). Alternatively, there may be two non-cross-nasal circuits (401), with the two non-cross-nasal circuits (401) located on the left and right sides of the vertical axis of symmetry of the rhinitis treatment patch, respectively. The positive and negative ends of the non-cross-nasal circuit (401) on the left side can communicate with the human tissue of the two perinasal acupoints (300) located on the left side of the vertical axis of symmetry of the rhinitis treatment patch, and the positive and negative ends of the non-cross-nasal circuit (401) on the right side can communicate with the human tissue of the two perinasal acupoints (300) located on the right side of the vertical axis of symmetry of the rhinitis treatment patch. Alternatively, the transnasal circuit (402) may be provided such that the positive and negative ends of the transnasal circuit (402) can communicate with human tissue at two perinasal acupoints (300) located on the left and right sides of the vertical axis of symmetry of the rhinitis treatment patch. Alternatively, there may be two transnasal circuits (402), wherein the positive and negative ends of each transnasal circuit (402) can communicate with the human tissue at the two perinasal acupoints (300) located on the left and right sides of the vertical axis of symmetry of the rhinitis treatment patch. The positive electrode (201) includes a base layer (201a), a flexible layer (201b), and a conductive layer (201c) disposed between the base layer (201a) and the flexible layer (201b). The conductive layer (201c) is provided with a conductive needle array (201c-1). A stretching section (101) is provided at the middle section of the patch body (100). The stretching section (101) connects the two ends of the patch body (100) in the lateral direction. The lateral deformation range of the stretching section (101) is 0~2.5cm; and, The acquisition module (500) is used to acquire pressure data from both sides of the nasal cavity, determine whether there is inflammation based on the pressure data, and if there is inflammation, generate inflammation degree data based on the pressure data. An electrical stimulation module (600) is used to electrically stimulate the acupoints (300) around the nose corresponding to the inflamed nasal cavity; The control module (700) switches the operation of the corresponding electrical stimulation module (600) according to the received result of whether there is inflammation in both nasal cavities. If there is inflammation in both nasal cavities, the current intensity and frequency of the electrical stimulation module (600) are adjusted according to the inflammation degree data of the two nasal cavities.

Images